To a large extent, TMB determines the immune response of cancer patients to treatment with immune checkpoint inhibitors (ICIs), either, anti-cytotoxic T cell-associated antigen 4 (CTLA-4) or anti-programmed cell death 1 (PD-1) (53–55). The gene discussed is CTLA4; the disease is cancer.